Cargando…
Clinical analysis of bevacizumab targeting therapy in treating early colorectal carcinoma after operation
Clinical effects of bevacizumab target therapy in treating early colorectal carcinoma (CRC) after resection were analyzed. Ninety-two patients diagnosed with early CRC and treated with endoscopic mucosal resection for the first time were selected for the study. They were randomly divided into the co...
Autores principales: | Li, Tie-Ling, Sun, Zhi-Guo, Jiang, Xiaoming, Guo, Hai-Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452938/ https://www.ncbi.nlm.nih.gov/pubmed/28599469 http://dx.doi.org/10.3892/ol.2017.6087 |
Ejemplares similares
-
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
por: Puthillath, Ajithkumar, et al.
Publicado: (2009) -
Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015) -
TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021) -
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
por: Escudier, Bernard, et al.
Publicado: (2008) -
Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)